Overview of treatment options for invasive fungal infections

Melanie W. Pound; Mary L. Townsend; Vincent Dimondi; Dustin Wilson; Richard H. Drew

doi:10.3109/13693786.2011.560197

Overview of treatment options for invasive fungal infections

Melanie W. Pound, Mary L. Townsend, Vincent Dimondi, Dustin Wilson, Richard H. Drew

Campbell University

Research output: Contribution to journal › Article › peer-review

Abstract

The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.

Original language	American English
Journal	Medical Mycology
Volume	49
DOIs	https://doi.org/10.3109/13693786.2011.560197
State	Published - Jan 1 2011

Keywords

echinocandins
azole antifungals
amphotericin

Disciplines

Pharmacy and Pharmaceutical Sciences

Access to Document

10.3109/13693786.2011.560197License: CC BY

https://doi.org/10.3109/13693786.2011.560197

Cite this

@article{6348523131084348bff3a186dfb2bee8,

title = "Overview of treatment options for invasive fungal infections",

abstract = " The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.",

keywords = "echinocandins, azole antifungals, amphotericin",

author = "Pound, {Melanie W.} and Townsend, {Mary L.} and Vincent Dimondi and Dustin Wilson and Drew, {Richard H.}",

year = "2011",

month = jan,

day = "1",

doi = "10.3109/13693786.2011.560197",

language = "American English",

volume = "49",

journal = "Medical Mycology",

}

TY - JOUR

T1 - Overview of treatment options for invasive fungal infections

AU - Pound, Melanie W.

AU - Townsend, Mary L.

AU - Dimondi, Vincent

AU - Wilson, Dustin

AU - Drew, Richard H.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.

AB - The introduction of several new antifungals has significantly expanded both prophylaxis and treatment options for invasive fungal infections (IFIs). Relative to amphotericin B deoxycholate, lipid-based formulations of amphotericin B have significantly reduced the incidence of nephrotoxicity, but at a significant increase in drug acquisition cost. Newer, broad-spectrum triazoles (notably voriconazole and posaconazole) have added significantly to both the prevention and treatment of IFIs, most notably Aspergillus spp. (with voriconazole) and the treatment of some emerging fungal pathogens. Finally, a new class of parenteral antifungals, the echinocandins, is employed most frequently against invasive candidal infections. While the role of these newer agents continues to evolve, this review summarizes the activity, safety and clinical applications of agents most commonly employed in the treatment of IFIs.

KW - echinocandins

KW - azole antifungals

KW - amphotericin

UR - https://cufind.campbell.edu/pharmacy/92

UR - https://doi.org/10.3109/13693786.2011.560197

UR - https://cufind.campbell.edu/pharmacypractice/650

U2 - 10.3109/13693786.2011.560197

DO - 10.3109/13693786.2011.560197

M3 - Article

C2 - 21366509

VL - 49

JO - Medical Mycology

JF - Medical Mycology

ER -

Overview of treatment options for invasive fungal infections

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this